DNA sequencing machine maker Illumina will have to find another way to “read” long pieces of genetic material as well as short stretches, the genomic giant’s bailiwick. Its $1.2 billion proposal to acquire long-read capability by buying rival Pacific Biosciences ended Thursday following challenges from antitrust regulators.
The deal foundered about 14 months after the companies first announced the plan to combine businesses. San Diego-based Illumina (NASDAQ: ILMN), which has built its business around what’s known as short-read sequencing, argued the acquisition would accelerate innovation in the field.
Although so called long reads have historically been more error-prone than… Read more »
UNDERWRITERS AND PARTNERS
